BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, June 5, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 19, 2020
View Archived Issues
Microbiome metabolites as immunotherapy adjuvants
Read More
Oxygen therapy harms lungs via lung, gut microbiome
Read More
Positive preclinical data presented for multi-target COVID-19 vaccine
Read More
T-2143, a novel HSP90-PI3K drug conjugate with promising activity in cancer models
Read More
Discovery of a novel FASN inhibitor with promising activity in model of AD
Read More
BrightGene Bio-Medical Technology identifies Gly12Cys mutant GTPase KRAS inhibitors
Read More
New PD-1/PD-L1 and/or PD-L1/CD80 interaction inhibitors patented by Betta Pharmaceuticals
Read More
Jiangsu Vcare Pharmatech discovers JAK inhibitors
Read More
Zhejiang Hisun Pharmaceutical presents new RET inhibitors
Read More
University of Queensland, Preveceutical Medical patent delta- and kappa-opioid receptor antagonists
Read More
Update on development of PGX-YBG inhalable therapeutic for COVID-19
Read More
First patient dosed in phase Ib study of ARO-HIF2 in clear cell renal cell carcinoma
Read More
Topline data presented from phase II study of elobixibat in NAFLD and NASH
Read More
FDA issues complete response letter for filgotinib for the treatment of RA
Read More
Promising interim data presented from phase II study of ERC-1671 in recurrent GBM
Read More
Phase II study of QBECO SSI in colorectal cancer approved in Israel
Read More
Evotec and Novo Nordisk collaborate to develop novel therapies for CKD
Read More
Targeting the adenosine A2A receptor may prevent osteoarthritis progression
Read More
